Premium
Non‐invasive ultrasound in the study of recombinant CTGF‐CT therapy in mice gastric cancer model (LB497)
Author(s) -
Lee Hsinyu,
Chang ChengChi,
Chen ChiaI,
Chen ChiungNien
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.lb497
Subject(s) - ctgf , recombinant dna , connective tissue , medicine , cancer , growth factor , in vivo , pathology , cancer research , oncology , biology , receptor , biochemistry , gene , microbiology and biotechnology
Aim: Connective tissue growth factor (CTGF) has been known to play important roles in normal physiological conditions as well as pathological conditions. In gastric cancer, previous study has shown that CTGF expression elevation blocks the adhesion of gastric cancer cells to peritoneum in vitro and in vivo. In this study we aimed to purify CTGF from E. coli using a His‐tag purification system and setup a non‐invasive small animal model to study the effect of recombinant CTGF in gastric cancer progression. Material and methods: Recombinant CTGF‐CT was purified using a His‐tag purification system. Gastric cancer cell was injected with or without recombinant CTGF‐CT into SCID mice intraperitoneally. Growth of gastric cancer tumor was observed using small animal ultrasound and survival was calculated using the Kaplan‐Meier survival probability assay. Results: Recombinant CTGF‐CT was shown to have about 50% inhibition in in vitro adhesion assay (p‐value < 0.001). Ultrasound scans have shown higher average tumor sizes and numbers in non‐treated, and vehicle treated group compared to recombinant CTGF‐CT treated group. 100% mortality of mice in recombinant CTGF‐CT treated group compared to vehicle treated group and non‐treated group were at 2 months and 7 days, 1.5 months, and 1 month respectively. Conclusion: Purified recombinant CTGF‐CT significantly reduced the number and size of gastric cancer tumors in mice determined using non‐invasive ultrasound and is a potential therapeutic drug in gastric cancer therapy. Grant Funding Source : Supported by National Science Councel, Taiwan